Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Berichten met het trefwoord ‘Bayer’

Bayer, J&J win second U.S. trial over Xarelto bleeding risks

A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the second trial to stem from thousands of lawsuits blaming injuries on the blood thinner Xarelto, the drug companies said on Monday.

Bron: Reuters Meer lezen »

Bayer’s lymphoma drug copanlisib gets speedy FDA review

Bayer could claim FDA approval for its follicular lymphoma drug copanlisib within six months, after being awarded priority review status by the US regulator. The German group filed for approval of the drug – an intravenous PI3K inhibitor – as a third-line treatment for patients with relapsed or refractory FL, the most common type of […]

Bron: PMLiVE Meer lezen »

J&J, Bayer face first jury trial over blockbuster Xarelto’s bleedings risks

The first federal trial over the bleeding risks of Xarelto, Johnson & Johnson and Bayer’s blockbuster anticoagulant, kicks off next week, with 18,000 more cases stacked up behind it. It will be the initial indicator of whether juries are likely to side with the drugmakers, ruling that their med is safe and effective, or patients, […]

Bron: FiercePharma Meer lezen »

Xarelto and Eylea continue to dominate Bayer’s pharma sales

Bayer turned in a strong performance in 2016, with pharmaceutical sales that rose 7.3% to €16.4bn driven by high growth from Xarelto and Eylea. Anticoagulant Xarelto (rivaroxaban) led the charge, rising 30% to bring in €2.9bn, with eye treatment Eylea (aflibercept) up 32% with sales of €1.6bn.

Bron: PMLiVE Meer lezen »

Looking back at the biggest deal of 2016: Bayer-Monsanto

The industry followed Bayer’s attempts to acquire US agricultural firm Monsanto with fevered anticipation; the takeover eventually closed in September for $66 billion, debt included. Winckworth Sherwood’s Catherine Moss delves into the implications of the biggest deal of 2016.  

Bron: InPharm.com Meer lezen »

Bayer applies for Regorafenib authorization to treat liver cancer

German drugmaker Bayer on Monday said it submitted an application to have its cancer drug Regorafenib approved for the second-line treatment of liver cancer patients following successful clinical trials.

Bron: Reuters Meer lezen »

Bayer CEO defends $66 billion Monsanto acquisition

Bayer AG’s chief executive Werner Baumann has spoken in defence of the company’s move last week to acquire US agricultural firm Monsanto for $66 billion, the biggest deal of the year so far.  

Bron: InPharm.com Meer lezen »

Bayer’s Monsanto acquisition to face politically charged scrutiny

 As the global agricultural sector races to consolidate, Bayer AG’s $66 billion all-cash deal to acquire Monsanto Co will test growing political and consumer unease in the United States and abroad over the future of food production.

Bron: Reuters Meer lezen »

Bayer ponders $1.1 billion portfolio sale to fund Monsanto acquisition

In the latest development in the Bayer-Monsanto saga, the German drugmaker has enlisted the aid of global financial services firm JPMorgan Chase to assess possible options with its dermatology unit, the sale of which could reportedly generate over $1.1 billion for the company.  

Bron: InPharm.com Meer lezen »

Bayer takes another shot at Monsanto acquisition

Bayer has made another move to acquire US-based Monsanto, raising the price it is prepared to pay in an effort to snare the agrochemical and agricultural biotech.

Bron: InPharm.com Meer lezen »

« Oudere artikelen |